Trial Profile
Interventional, Open-label, Flexible-dose Study of Vortioxetine on Emotional Functioning in Patients With Major Depressive Disorder With Inadequate Response to SSRI/SNRI Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms COMPLETE
- Sponsors Lundbeck A/S
- 15 Feb 2023 Results of an analysis assessing clinically relevant response threshold for motivation and energy inventory in patients with major depressive disorder receiving antidepressant treatment published in the Journal of Affective Disorders
- 01 Nov 2021 Results of an analysis assessing the validaty of the Oxford Depression Questionnaire (ODQ) is a patient-reported scale for assessing emotional blunting in patients with major depressive disorder a published in the Journal of Affective Disorders
- 15 Mar 2021 Primary endpoint (Change from baseline to Week 8 in Oxford Depression Questionnaire (ODQ) total score) has been met.